CL2024003362A1 - Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina - Google Patents

Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina

Info

Publication number
CL2024003362A1
CL2024003362A1 CL2024003362A CL2024003362A CL2024003362A1 CL 2024003362 A1 CL2024003362 A1 CL 2024003362A1 CL 2024003362 A CL2024003362 A CL 2024003362A CL 2024003362 A CL2024003362 A CL 2024003362A CL 2024003362 A1 CL2024003362 A1 CL 2024003362A1
Authority
CL
Chile
Prior art keywords
degraders
heterobifunctional
bcl
compounds
tetrahydroisoquinoline
Prior art date
Application number
CL2024003362A
Other languages
English (en)
Spanish (es)
Inventor
J Horn Evan
D Hansen Joshua
d alexander Matthew
Huang Fei
a nagy Mark
Original Assignee
Treeline Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeline Biosciences Inc filed Critical Treeline Biosciences Inc
Publication of CL2024003362A1 publication Critical patent/CL2024003362A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024003362A 2022-05-06 2024-11-04 Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina CL2024003362A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263339253P 2022-05-06 2022-05-06
US202263398783P 2022-08-17 2022-08-17
US202263429862P 2022-12-02 2022-12-02
US202363449756P 2023-03-03 2023-03-03
US202363454545P 2023-03-24 2023-03-24
US202363457997P 2023-04-07 2023-04-07

Publications (1)

Publication Number Publication Date
CL2024003362A1 true CL2024003362A1 (es) 2025-03-07

Family

ID=86688472

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024003362A CL2024003362A1 (es) 2022-05-06 2024-11-04 Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina

Country Status (13)

Country Link
US (1) US20240238423A9 (enExample)
EP (1) EP4519259A1 (enExample)
JP (1) JP2025517642A (enExample)
KR (1) KR20250008772A (enExample)
CN (1) CN119343345A (enExample)
AU (1) AU2023264018A1 (enExample)
CA (1) CA3251489A1 (enExample)
CL (1) CL2024003362A1 (enExample)
IL (1) IL316465A (enExample)
MX (1) MX2024013537A (enExample)
PE (1) PE20250007A1 (enExample)
TW (1) TW202400589A (enExample)
WO (1) WO2023215482A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202527930A (zh) * 2023-11-07 2025-07-16 美商樹線生物科學公司 四氫異喹啉異雙功能bcl-xl降解劑
TW202535872A (zh) * 2023-11-07 2025-09-16 美商樹線生物科學公司 四氫異喹啉異雙功能bcl-xl降解劑
WO2025101575A1 (en) * 2023-11-07 2025-05-15 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2025130875A1 (zh) * 2023-12-18 2025-06-26 南京瑞初医药有限公司 氮杂环化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
CN113660937A (zh) 2019-02-08 2021-11-16 佛罗里达大学研究基金公司 治疗剂和治疗方法
AU2020310147A1 (en) 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
CN112707900B (zh) 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
US12441722B2 (en) 2020-01-15 2025-10-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
US20230167105A1 (en) 2020-04-28 2023-06-01 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
US20250197387A1 (en) 2021-09-17 2025-06-19 Kymera Therapeutics, Inc. Bcl-xl degraders and uses thereof
EP4431511A4 (en) * 2021-11-09 2025-10-15 Hangzhou Glubio Pharmaceutical Co Ltd WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE

Also Published As

Publication number Publication date
EP4519259A1 (en) 2025-03-12
TW202400589A (zh) 2024-01-01
PE20250007A1 (es) 2025-01-07
WO2023215482A1 (en) 2023-11-09
US20240238423A9 (en) 2024-07-18
MX2024013537A (es) 2024-12-06
JP2025517642A (ja) 2025-06-10
AU2023264018A1 (en) 2024-11-07
CA3251489A1 (en) 2023-11-09
US20230390404A1 (en) 2023-12-07
CN119343345A (zh) 2025-01-21
IL316465A (en) 2024-12-01
KR20250008772A (ko) 2025-01-15

Similar Documents

Publication Publication Date Title
CL2024003362A1 (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
CO2026003544A2 (es) Degradadores bifuncionales de quinolona tricíclica bcl6
CL2024003831A1 (es) Degradadores heterobifuncionales de bcl6 de 1,8-naftiridin-2-ona
CO2024017749A2 (es) Degradadores bifuncionales de bcl6 de quinolona tricíclica
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
PE20230238A1 (es) Inhibidores de kras g12c
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
ES2161442T3 (es) Analogos de coralina como inhibidores de topoisomerasa.
PA8436001A1 (es) Inhibidores de naaladasa.
BR0002515A (pt) Derivados de 4-arilpiperidina para o tratamento do prurido
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
BR0002518A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
DE3478810D1 (en) Benzazocinone and benzazoninone derivatives, process for their preparation, pharmaceutical preparations containing these compounds, and their therapeutical use
MX2024013311A (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CL2025000529A1 (es) Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer.
ATE368040T1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
MX2024013312A (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
CL2024003797A1 (es) Compuestos derivados de 2-oxo-1,2-dihidroquinolina que degradan bcl6, composición y uso para tratar el cancer.
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
AR129220A1 (es) Degradadores de bcl-xl heterobifuncionales de tetrahidroisoquinolina
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
AR133791A1 (es) Degradadores bifuncionales de bcl6 de quinolona tricíclica